Dr Reddys Stock Today

RDY
 Stock
  

USD 56.40  0.28  0.50%   

Market Performance
6 of 100
Odds Of Distress
Less than 11
Dr Reddys is trading at 56.40 as of the 2nd of December 2022; that is 0.50 percent up since the beginning of the trading day. The stock's open price was 56.12. Dr Reddys has less than a 11 % chance of experiencing some financial distress in the next two years of operation, but did not have a good performance during the last 90 trading days. Equity ratings for Dr Reddys Laboratories are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 12th of December 2020 and ending today, the 2nd of December 2022. Click here to learn more.
CUSIP
256135203
Fiscal Year End
March
Business Domain
Pharmaceuticals, Biotechnology & Life Sciences
IPO Date
11th of April 2001
Category
Healthcare
Classification
Health Care
Reddys Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. Reddys Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India. Dr Reddys operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on New York Stock Exchange. The company has 166.03 M outstanding shares of which 1.3 M shares are at this time shorted by investors with about 5.64 days to cover. More on Dr Reddys Laboratories

Moving against Dr Reddys

-0.6ARTLArtelo Biosciences Fiscal Year End 5th of December 2022 PairCorr
Follow Valuation Odds of Bankruptcy
Check how we calculate scores

Dr Reddys Stock Highlights

Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. Dr Reddys' investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Dr Reddys or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
Latest headline from news.google.com: Dr. Reddys Laboratories To Face Antitrust Litigation, Along With Other Generic Pharma Companies In US, - Inventiva
CEOMARC KIKUCHI
Thematic IdeaObamacare (view all)
Fama & French Classification
Average Analyst Recommendation
Analysts covering Dr Reddys report their recommendations after researching Dr Reddys' financial statements, talking to executives and customers, or listening in on Dr Reddys' conference calls. The current trade recommendation is based on an ongoing consensus estimate among financial analysts covering Dr Reddys Laboratories. The Dr Reddys consensus assessment is calculated by taking the average forecast from all of the analysts covering Dr Reddys.
Macroaxis Advice
Unlike general analyst consensus, Macroaxis buy hold or sell recommendation is provided in the context of your current investment horizon and risk tolerance. The advice algorithm takes into account all of Dr Reddys' available fundamental, technical, and predictive indicators. Your current horizon is 90 days - details
Strong HoldOvervalued
Dr Reddys Laboratories (RDY) is traded on New York Stock Exchange in USA and employs 24,795 people. Dr Reddys is listed under Pharmaceuticals category by Fama And French industry classification. The company currently falls under 'Mid-Cap' category with total capitalization of 9.35 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Dr Reddys's market, we take the total number of its shares issued and multiply it by Dr Reddys's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and these looking for more risk prefer small-cap and mid-cap equities. Dr Reddys Laboratories runs under Pharmaceuticals sector within Health Care industry. The entity has 166.03 M outstanding shares of which 1.3 M shares are at this time shorted by investors with about 5.64 days to cover. Dr Reddys Laboratories has about 75 M in cash with 28.11 B of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 208.58.
Check Dr Reddys Probability Of Bankruptcy
Ownership
Dr Reddys Laboratories shows a total of 166.03 Million outstanding shares. About 90.0 % of Dr Reddys outstanding shares are held by regular investors with 0.0 percent owned by insiders and only 10.3 (percent) by institutions. Note that regardless of who owns the company, if the true value of the entity is less than the market is willing to pay for it, you may not be able to generate positive returns over time.

Ownership Allocation (%)

Check Dr Reddys Ownership Details

Dr Reddys Stock Price Odds Analysis

Based on a normal probability distribution, the odds of Dr Reddys jumping above the current price in 90 days from now is nearly 4.8%. The Dr Reddys Laboratories probability density function shows the probability of Dr Reddys stock to fall within a particular range of prices over 90 days. Considering the 90-day investment horizon Dr Reddys has a beta of 0.6077 indicating as returns on the market go up, Dr Reddys average returns are expected to increase less than the benchmark. However, during the bear market, the loss on holding Dr Reddys Laboratories will be expected to be much smaller as well. Additionally, the company has an alpha of 0.0358, implying that it can generate a 0.0358 percent excess return over NYSE Composite after adjusting for the inherited market risk (beta).
  Odds Below 56.4HorizonTargetOdds Above 56.4
95.11%90 days
 56.40 
4.80%
Based on a normal probability distribution, the odds of Dr Reddys to move above the current price in 90 days from now is nearly 4.8 (This Dr Reddys Laboratories probability density function shows the probability of Dr Reddys Stock to fall within a particular range of prices over 90 days) .

Dr Reddys Laboratories Risk Profiles

Investors will always prefer to have the highest possible return on investment while minimizing volatility. Dr Reddys market risk premium is the additional return an investor will receive from holding Dr Reddys long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Dr Reddys. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Although Dr Reddys' alpha and beta are two of the key measurements used to evaluate Dr Reddys' performance over the market, the standard measures of volatility play an important role as well.

Dr Reddys Stock Against Markets

Picking the right benchmark for Dr Reddys stock is fundamental to making educated investment choices. Many naive investors compare their positions with the S&P 500 or with the Nasdaq. But these benchmarks are not all-inclusive and generally should be used only for large-capitalization equities or stock offerings from large companies. When the price of a selected benchmark declines in a down market, there may be an uptick in Dr Reddys stock price where buyers come in believing the asset is cheap. The opposite is true when the market is bullish; so, accurately picking the benchmark for Dr Reddys is critical whether you are bullish or bearish towards Dr Reddys Laboratories at a given time.

Be your own money manager

Our tools can tell you how much better you can do entering a position in Dr Reddys without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Idea Breakdown Now

   

Idea Breakdown

Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes
All  Next Launch Module

Dr Reddys Corporate Directors

Dr Reddys corporate directors refer to members of a Dr Reddys board of directors. The board of directors generally takes responsibility for the Dr Reddys' affairs and long-term direction of the entity. A corporate director does not make decisions for the corporation on his own. As a member of the board of directors, she or he must function as a part of a group that makes decisions on behalf of the business only by the board of directors' meetings. To pass a resolution, a majority of Dr Reddys' board members must vote for the resolution. The Dr Reddys board of directors' duties also include the election, removal, and supervision of officers, including the adoption, amendment, and repeal of bylaws.
Leo Puri - Non-Executive Independent DirectorProfile
Ravi Bhoothalingam - Non-Executive Independent DirectorProfile
Prasad Menon - Lead Non-Executive Independent DirectorProfile
Shikha Sharma - Non-Executive Independent DirectorProfile

Invested in Dr Reddys Laboratories?

The danger of trading Dr Reddys Laboratories is mainly related to its market volatility and company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Dr Reddys is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Dr Reddys. The Shape ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Dr Reddys Laboratories is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
Additionally, take a look at Your Equity Center. Note that the Dr Reddys Laboratories information on this page should be used as a complementary analysis to other Dr Reddys' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Equity Forecasting module to use basic forecasting models to generate price predictions and determine price momentum.

Complementary Tools for Dr Reddys Stock analysis

When running Dr Reddys Laboratories price analysis, check to measure Dr Reddys' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Dr Reddys is operating at the current time. Most of Dr Reddys' value examination focuses on studying past and present price action to predict the probability of Dr Reddys' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Dr Reddys' price. Additionally, you may evaluate how the addition of Dr Reddys to your portfolios can decrease your overall portfolio volatility.
Focused Opportunities
Build portfolios using our predefined set of ideas and optimize them against your investing preferences
Go
Transaction History
View history of all your transactions and understand their impact on performance
Go
Positions Ratings
Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance
Go
Probability Of Bankruptcy
Get analysis of equity chance of financial distress in the next 2 years
Go
Price Transformation
Use Price Transformation models to analyze depth of different equity instruments across global markets
Go
CEO Directory
Screen CEOs from public companies around the world
Go
Efficient Frontier
Plot and analyze your portfolio and positions against risk-return landscape of the market.
Go
Idea Breakdown
Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes
Go
Is Dr Reddys' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Dr Reddys. If investors know Dr Reddys will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Dr Reddys listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth YOY
0.12
Market Capitalization
9.3 B
Quarterly Revenue Growth YOY
0.094
Return On Assets
0.0903
Return On Equity
0.16
The market value of Dr Reddys Laboratories is measured differently than its book value, which is the value of Dr Reddys that is recorded on the company's balance sheet. Investors also form their own opinion of Dr Reddys' value that differs from its market value or its book value, called intrinsic value, which is Dr Reddys' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Dr Reddys' market value can be influenced by many factors that don't directly affect Dr Reddys' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Dr Reddys' value and its price as these two are different measures arrived at by different means. Investors typically determine Dr Reddys value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Dr Reddys' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.